The journal Nature Medicine have reported that a number of ocular researchers have raised criticisms of a diabetic macular oedema (DME) clinical trial for using Lucentis but not Avastin (bevacizumab). Avastin, currently used off-label by many ophthalmologists as it may be up to 20 times cheaper per dose than Lucentis, was not included in the clinical study.